Bioventus (BVS) Enterprise Value (2021 - 2026)

Bioventus (BVS) has reported Enterprise Value for 6 consecutive years, with $841.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 48.39% year-over-year to $841.2 million; the trailing twelve-month figure through Jun 2026 stood at $841.2 million (up 48.39% YoY), and the FY2025 full-year result was $609.8 million, down 28.46% from the prior year.
• Enterprise Value advanced to $841.2 million in Q2 2026 per BVS's latest filing, from $755.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at $1.1 billion in Q2 2022 and bottomed at $88.5 million in Q2 2023.
• Historically, Enterprise Value has averaged $572.2 million across 5 years, with a median of $558.5 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value tumbled 91.89% in 2023, then surged 391.37% in 2024.
• Over 5 years, Enterprise Value stood at $260.0 million in 2022, then surged by 64.32% to $427.2 million in 2023, then surged by 99.52% to $852.3 million in 2024, then fell by 28.46% to $609.8 million in 2025, then soared by 37.95% to $841.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $841.2 million, $755.3 million, and $609.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.